UNC Antibody

What are the fundamental principles of antibody validation at UNC?

Antibody validation at UNC follows an eight-step framework for rigorous and reproducible experiments in biomolecular research. Researchers must ensure that all antibodies are fully validated before use in experiments. For immunohistochemistry (IHC) projects, the Pathology Services Core strongly recommends consulting with them to discuss project details and factors affecting reproducibility . UNC recommends using highly validated antibodies that are approved for In Vitro Diagnostic Use (IVD) when available. If such antibodies are not available, researchers should select antibodies from vendors who provide comprehensive validation information . The validation process should include specificity testing, application-specific validation, and documentation of all validation steps in accordance with UNC's research reproducibility guidelines.

How should researchers design experiments with antibodies to ensure reproducibility?

Researchers at UNC should follow the eight-step process for rigorous and reproducible experiments when designing antibody-based studies. This includes:

• Consulting with core facility staff during the planning stage

• Designing experiments with sufficient controls (for rigor) and replicates (for reproducibility)

• Ensuring all reagents, including antibodies, are fully validated

• Following clear and detailed protocols (SOPs) with well-documented data analysis plans

• Ensuring all staff are well-trained and understand each experimental step

• Using only well-maintained instrumentation

• Documenting all steps, reagents, equipment, and data analysis methods

• Properly acknowledging grant support and core facilities in publications

For antibody-specific considerations, researchers should validate antibodies for their specific application (western blotting, immunofluorescence, or immunoprecipitation) as performance can vary significantly between applications. A study highlighted by the NC3Rs found that many antibodies against neuroscience-related proteins failed characterization experiments in at least one of three commonly used applications .

What documentation should accompany antibody use in UNC research?

Documentation for antibody use in UNC research must be comprehensive and follow institutional guidelines for rigor and reproducibility. Researchers should:

• Document the source and catalog number of all antibodies

• Record batch/lot numbers to account for potential batch variations

• Maintain detailed records of all validation experiments performed

• Document specific application conditions (dilutions, incubation times, buffers)

• Store all experimental data and documentation in a safe data management repository

According to findings presented in the NC3Rs meeting report, 88.4% of papers using antibodies in immunofluorescence did not present any relevant validation data . To address this issue, UNC researchers are encouraged to maintain comprehensive documentation of validation procedures and to include this information in publications to improve research reproducibility.

How do UNC researchers develop novel antibody tests with high specificity?

UNC researchers have developed sophisticated approaches to create highly specific antibody tests. For example, UNC School of Medicine scientists developed a COVID-19 antibody test that targets a unique piece of the SARS-CoV-2 spike protein called the receptor binding domain (RBD) . This methodological approach involves:

• Identifying unique protein domains not shared among related pathogens

• Creating assays that target these specific domains

• Validating specificity by testing against samples exposed to related pathogens

• Correlating antibody binding with neutralizing activity

In the case of the RBD-based test, researchers confirmed that the RBD of the SARS-CoV-2 spike protein is not shared among other known human or animal coronaviruses, making antibodies against this domain highly specific to SARS-CoV-2. When testing blood collected from people exposed to other coronaviruses, none had antibodies to the RBD of SARS-CoV-2, confirming the test's specificity .

What techniques are employed to identify cross-reactive antibodies for multiple viral variants?

Identifying cross-reactive antibodies involves sophisticated screening and validation techniques. A collaborative research team from Duke University and UNC-Chapel Hill demonstrated this approach when they identified an antibody effective against multiple coronaviruses . Their methodology included:

• Blood sample collection from patients with different coronavirus infections (e.g., SARS-CoV-1 and SARS-CoV-2)

• Isolation and screening of large antibody libraries (over 1,700 antibodies in the Duke-UNC study)

• Selection of antibodies that bind to multiple coronavirus variants

• Further analysis to identify the most potent cross-binding candidates

• Testing of binding specificity against a range of animal and human coronaviruses

• Identification of conserved binding sites that remain unchanged despite viral mutations

This methodological approach successfully identified an antibody that binds to coronaviruses at locations conserved across numerous mutations and variations, making it effective against both SARS-CoV-1 and SARS-CoV-2, as well as various animal coronaviruses .

How can researchers troubleshoot antibody-related reproducibility issues?

Troubleshooting antibody-related reproducibility issues requires systematic analysis and methodical problem-solving. When researchers encounter reproducibility challenges, they should:

• Verify antibody specificity through additional validation experiments

• Check for batch-to-batch variations by comparing lot numbers

• Reassess experimental conditions, including buffer compositions and incubation parameters

• Implement additional controls to identify potential cross-reactivity

• Consider consulting with core facility experts for technical guidance

According to findings reported by NC3Rs, antibodies against 65 neuroscience-related proteins failed characterization experiments in at least one of three commonly used applications, and each of these proteins was linked to approximately 12 published papers that presented data using poorly performing antibodies . This highlights the importance of thorough validation and troubleshooting to prevent perpetuating reproducibility issues.

What controls should be included when validating antibodies for specific applications?

Proper antibody validation requires a comprehensive set of controls tailored to the specific application. For rigorous validation, researchers should include:

When designing experiments, UNC researchers are advised to include sufficient controls for rigor and replicates for reproducibility . The specific controls should be selected based on the application and the nature of the experiment, with documentation of all validation steps.

How do UNC researchers determine the optimal concentration and conditions for antibody use?

Determining optimal antibody concentration and conditions involves systematic titration and validation processes. UNC researchers should:

• Perform antibody titration experiments with a range of concentrations

• Test various buffer compositions to optimize signal-to-noise ratio

• Evaluate different incubation times and temperatures

• Assess blocking reagents to minimize non-specific binding

• Validate optimized conditions with appropriate positive and negative controls

For specialized applications such as immunohistochemistry, the Pathology Services Core recommends consulting with core staff during the planning stage to design experiments that ensure reproducibility . This includes determining optimal antibody dilutions, incubation conditions, and antigen retrieval methods specific to each tissue type and fixation method.

What strategies are recommended for validating antibodies against emerging pathogens?

Validating antibodies against emerging pathogens presents unique challenges requiring specialized approaches. Based on UNC's research on COVID-19 antibodies, recommended strategies include:

• Identifying conserved epitopes across variant strains

• Performing cross-reactivity testing against related pathogens

• Correlating binding activity with functional neutralization assays

• Using bioinformatic analysis to predict epitope conservation

• Implementing rapid validation workflows for emerging variants

In their work on SARS-CoV-2, UNC researchers created an antibody test targeting the RBD of the spike protein, which proved highly specific for SARS-CoV-2 and did not cross-react with other coronaviruses . Similarly, the collaborative research between Duke and UNC identified antibodies that bind to coronaviruses at locations that remain conserved despite mutations, making them potentially effective against future variants .

How should researchers interpret contradictory antibody validation results?

When faced with contradictory antibody validation results, researchers should follow a systematic approach to resolve discrepancies:

• Evaluate technical variables (reagent quality, equipment calibration, protocol execution)

• Consider biological variables (sample heterogeneity, expression levels)

• Assess antibody-specific factors (lot variation, storage conditions, specificity for different epitopes)

• Implement orthogonal validation methods to confirm target specificity

• Consult with core facility experts for technical guidance

Research from the NC3Rs meeting highlighted that antibodies can perform differently across applications, with many failing in at least one common application (western blotting, immunofluorescence, or immunoprecipitation) . Therefore, contradictory results may reflect genuine application-specific limitations rather than experimental error. Researchers should document these contradictions transparently in their publications to advance the field's understanding of antibody performance characteristics.

What statistical approaches are recommended for analyzing antibody binding data?

Statistical analysis of antibody binding data should be rigorous and appropriate to the experimental design. UNC researchers should:

• Consult with statisticians during experimental planning for power analysis

• Implement sufficient biological and technical replicates to enable robust statistical analysis

• Apply appropriate statistical tests based on data distribution and experimental design

• Consider multiple testing corrections when analyzing large datasets

• Report statistical methods and results transparently in publications

How can researchers distinguish between specific and non-specific antibody binding in complex samples?

Distinguishing specific from non-specific binding requires methodical validation and appropriate controls. Researchers should:

• Implement a comprehensive panel of controls, including:

  • Isotype controls to account for non-specific binding

  • Blocking peptide competition assays to confirm epitope specificity

  • Knockout/knockdown validation when possible

• Perform dose-response experiments to evaluate binding characteristics

• Use orthogonal detection methods to confirm target identity

• Consider pre-absorption steps to reduce background in complex samples

• Evaluate signal patterns for consistency with expected target localization or molecular weight

UNC's guidelines for rigor and reproducibility emphasize the importance of fully validated reagents and sufficient controls . By implementing these approaches, researchers can confidently distinguish specific antibody interactions from background or non-specific binding events.

How can researchers access UNC's antibody validation resources and expertise?

UNC offers various resources and expertise to support antibody-based research:

• Core facilities with specialized equipment and expert staff

• Consultation services for experimental design and troubleshooting

• Access to validated antibody panels for common research applications

• Training programs for proper antibody handling and experimental techniques

• Collaborative opportunities with antibody development experts

UNC guidelines recommend consulting with core facility staff in the planning stage of experiments . For immunohistochemistry projects specifically, the Pathology Services Core strongly recommends that PIs contact them to discuss project details and factors affecting reproducibility . Similarly, the Human Pluripotent Cell Core encourages researchers to consult with core staff for questions related to experimental design and IRB approval for patient samples .

What are the recommended practices for sharing antibody validation data within the research community?

To improve research reproducibility, UNC researchers should follow these practices when sharing antibody validation data:

• Include comprehensive validation information in publications, including:

  • Antibody source, catalog number, and lot number

  • Detailed validation protocols with all relevant controls

  • Application-specific validation results

  • Known limitations or caveats

• Share raw validation data through appropriate repositories

• Use Research Resource Identifiers (RRIDs) to unambiguously identify antibodies

• Contribute validation data to community resources when possible

• Document negative results to prevent perpetuation of poor reagents

The NC3Rs meeting report highlighted that 88.4% of papers using antibodies in immunofluorescence did not present any relevant validation data . To address this issue, the NC3Rs is facilitating the adoption of RIVER recommendations and working with funders and journals to encourage their widespread adoption, similar to the successful implementation of the ARRIVE guidelines .

What emerging trends are shaping the future of antibody research at UNC?

Several emerging trends are influencing antibody research at UNC and similar institutions:

• Increased emphasis on validation and reproducibility standards

• Development of non-animal derived antibodies and alternative affinity reagents

• Implementation of automated validation workflows for higher throughput

• Integration of computational approaches for antibody design and epitope prediction

• Expansion of cross-reactive antibody development for emerging pathogens

The NC3Rs is reviewing policies and application processes to encourage greater consideration of how reagents impact reproducibility, including encouraging the application of more reproducible non-animal derived antibodies and affinity reagents . Additionally, collaborative efforts between institutions, such as the Duke-UNC collaboration that identified cross-reactive coronavirus antibodies , highlight the trend toward multi-institutional approaches to address complex antibody research challenges.

How can researchers contribute to improving antibody research standards?

Researchers can contribute to improving antibody research standards through several approaches:

• Implementing rigorous validation protocols for all antibodies used in research

• Documenting and sharing validation data, including negative results

• Using Research Resource Identifiers (RRIDs) to unambiguously identify antibodies

• Contributing to collaborative validation efforts and databases

• Participating in community-driven initiatives to establish best practices